Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome.


Journal

Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 17 02 2020
accepted: 31 05 2020
pubmed: 14 6 2020
medline: 12 5 2021
entrez: 14 6 2020
Statut: ppublish

Résumé

This study aimed at determining socio-demographic and clinical factors of primary Sjögren syndrome (pSS) associated with osteoporosis (OP) and fragility fracture. SJOGRENSER is a cross-sectional study of patients with pSS, classified according to American European consensus criteria developed in 33 Spanish rheumatology departments. Epidemiological, clinical, serological and treatment data were collected and a descriptive analysis was conducted. Bivariate and multivariate analyses were performed using a binomial logistic regression to study the factors associated with OP and fragility fracture in pSS. 437 patients were included (95% women, with a median age of 58.6 years). 300 women were menopausal (76.4%). Prevalence of OP was 18.5% [in men (N = 21) this measured 19%]. A total of 37 fragility fractures were recorded. In the multivariate analysis, there was an association between OP and age: in the 51-64 age range (menopausal women), the OR measured 9.993 (95% CI 2301-43,399, p = 0.002); In the age > 64 years group, OR was 20.610 (4.679-90.774, p < 0.001); between OP and disease duration, OR was 1.046 (1.008-1085, p = 0.017); past treatment with corticosteroids, OR 2.548 (1.271-5.105, p = 0.008). Similarly, an association was found between fragility fractures and age: in the 51-64 age group, OR measured 5.068 (1.117-22,995, p = 0.035), age > 64 years, OR was 7.674 (1.675-35,151, p < 0.009); disease duration, OR 1.049 (CI 1.003-1097, p < 0.036) and the ESSDAI index, OR 1.080 (1.029-1134, p = 0.002). Patients with pSS can develop osteoporosis and fragility fractures over the course of the disease. Age, corticosteroids treatment and disease duration were associated with the development of OP. Disease duration and ESSDAI were associated with the development of fractures in patients with pSS.

Identifiants

pubmed: 32533289
doi: 10.1007/s00296-020-04615-3
pii: 10.1007/s00296-020-04615-3
doi:

Substances chimiques

Glucocorticoids 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1259-1265

Auteurs

Tarek Carlos Salman-Monte (TC)

Rheumatology Department, Hospital del Mar/Parc de Salut Mar-IMIM, Passeig Maritim 25-29, 08005, Barcelona, Spain. tareto4@gmail.com.

Carlos Sanchez-Piedra (C)

Unidad de Investigación de la SER, Madrid, Spain.

Monica Fernandez Castro (M)

Rheumatology Department, Hospital Puerta de Hierro, Madrid, Spain.

Jose Luis Andreu (JL)

Rheumatology Department, Hospital Puerta de Hierro, Madrid, Spain.

Victor Martinez Taboada (V)

Rheumatology Department, Hospital Marqués de Valdecilla, Santander, Spain.

Alejandro Olivé (A)

Rheumatology Department, Hospital Germans Trias i Pujol, Barcelona, Spain.

José Rosas (J)

Rheumatology Department, Hospital Marina Baixa, Alicante, Spain.

Raúl Menor (R)

Rheumatology Department, Hospital General Jerez de la Frontera, Madrid, Spain.

Beatriz Rodríguez (B)

Rheumatology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

Angel Garcia Aparicio (A)

Rheumatology Department, Hospital Virgen de la Salud, Toledo, Spain.

Francisco Javier Lopez Longo (FJ)

Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain.

Sara Manrique-Arija (S)

Rheumatology Department, Hospital Carlos Haya, Malaga, Spain.

Jesus Alberto Garcia Vadillo (JA)

Rheumatology Department, Hospital de la Princesa, Madrid, Spain.

Susana Gil Barato (S)

Rheumatology Department, Hospital General de Alicante, Alicante, Spain.

Ruth López-González (R)

Rheumatology Department, Hospital Virgen de la Concha, Zamora, Spain.

Carlos Galisteo (C)

Rheumatology Department, Hospital Parc-Taulí, Sabadell, Spain.

Jorge Gonzalez Martin (J)

Rheumatology Department, Hospital Madrid Norte Sanchinarro, Madrid, Spain.

Esther Ruiz Lucea (E)

Rheumatology Department, Hospital de Basurto, Vizcaya, Spain.

Celia Erausquin (C)

Rheumatology Department, Hospital de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.

Sheila Melchor (S)

Rheumatology Department, Hospital Doce de Octubre, Madrid, Spain.

Begoña Moreira (B)

Rheumatology Department, Complejo hospitalario de Pontevedra, Pontevedra, Spain.

Enrique Raya (E)

Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain.

Jose María Pego-Reigosa (JM)

Rheumatology Department, Hospital Universitario de Vigo, IRIDIS-VIGO Group, Galicia Sur Health Research, Vigo, Spain.

Natalia Cid (N)

Rheumatology Department, Hospital de Valme, Seville, Spain.

Enrique Júdez (E)

Rheumatology Department, Hospital de Albacete, Albacete, Spain.

Clara Moriano (C)

Rheumatology Department, Hospital de León, León, Spain.

Francisco Javier Narváez (FJ)

Rheumatology Department, Hospital de Bellvitge, Barcelona, Spain.

Hèctor Corominas (H)

Rheumatology Department, Hospital Sant Joan Despí Moisès Broggi, Barcelona, Spain.

Blanca Garcia Magallon (B)

Rheumatology Department, Hospital Miguel Servet, Zaragoza, Spain.

Carlos Guillen Astete (C)

Rheumatology Department, Hospital Ramón y Cajal, Madrid, Spain.

Ivan Castellvi (I)

Rheumatology Department, Hospital San Pau y Santa Creu, Barcelona, Spain.

Cristina Bohórquez (C)

Rheumatology Department, Hospital Príncipe de Asturias, Alcalá de Henares, Spain.

Javier Loricera (J)

Rheumatology Department, Hospital Marqués de Valdecilla, Santander, Spain.

Joaquín Belzunegui (J)

Rheumatology Department, Hospital de Donostia, Donostia-San Sebastián, Spain.

Óscar Illera (Ó)

Rheumatology Department, Hospital Infanta Sofía, Madrid, Spain.

Vicenç Torrente-Segarra (V)

Rheumatology Department, Hospital Comarcal Alt Penedès, Vilafranca del Penedès, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH